Clinical Trials Cultivation Data Treatment 
Cannabis Law Report
JUNE 16, 2021
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.
Cannabis Law Report
OCTOBER 6, 2021
Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veriheal
AUGUST 22, 2022
Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. We are currently recruiting patients, and data-capturing all the questionnaires and feedback from the patients for the live study. Quite frankly, the clinical trials couldn’t have come at a better time.
Cannabis Law Report
FEBRUARY 2, 2022
– Flora seeks approval to take their patent-pending, cannabinoid-based product through clinical trials under an EUA from INVIMA (Colombian FDA). Dr. Manalo-Morgan has spent the last 5 years researching cannabis and has specialized in the formulation of cannabinoid products for clinical trials.
Veriheal
APRIL 11, 2022
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Additionally, numerous other cannabis-based medications have already gained approval or are in the process of being tested in clinical trials. Fortunately, the U.S. This means that U.S.
Cannabis Law Report
JULY 4, 2019
The programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications including pain and cancer, as well as characterise cannabis-based medicinal products in disease models with particular focus of chronic pain, spasticity and cancer. About EMMAC.
The Joint Blog
JANUARY 12, 2020
Passage of the 2018 Farm Bill, which eased federal legal restrictions on hemp cultivation and transport, unleashed a stampede of companies rushing products to the market in an absence of regulations ensuring safety, quality and effectiveness. Products for people were swiftly followed by CBD chewies, oils and sprays for pets. “The
Expert insights. Personalized for you.
104 
Let's personalize your content